Impact of tacrolimus peak concentration on kidney graft outcomes
Open Access
- 17 August 2026
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 39, 16212
Abstract
Low tacrolimus (Tac) trough concentration-to-dose ratio (C0/D ratio) identifies kidney transplant patients with high level of Tac metabolization and is associated with poorer outcomes. We hypothesized that fast metabolization is associated with higher maximal Tac blood concentration (Cmax) and that Tac Cmax has a detrimental effect by itself. We retrospectively selected consecutive kidney transplant patients who (i) were treated by Tac, (ii) had systematic pharmacokinetic evaluation at 3- and 12-month posttransplant, and (iii) with a minimal follow-up of 5 years. Association between Tac Cmax/C0 with traditional transplant outcomes was analysed. 519 patients with a median follow-up of 8 years were included. Fast metabolizers displayed significantly higher median Cmax (20 vs. 17 ng/mL p < 0.001). Death-censored graft survival (DCGS) was significantly lower for patients with the highest Cmax/C0 values (Log rank, p = 0.05). In multivariate cox analysis, higher Cmax/C0 was independently associated with DCGS (HR = 1.37 [1.01; 1.87], p = 0.043). Our data support the hypothesis that exposure to high Cmax is detrimental and that fast metabolizers exhibit higher Tac Cmax even in situations where Tac C0 is not elevated. Tac formulations prone to mitigate pharmacokinetic peak could thus be particularly beneficial to fast metabolizers and should be evaluated in this indication.Keywords
Funding Information
- Chiesi Farmaceutici
This publication has 24 references indexed in Scilit:
- OPTN/SRTR 2021 Annual Data Report: KidneyAmerican Journal of Transplantation, 2023
- Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantationScientific Reports, 2021
- Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic reviewTransplantation Reviews, 2021
- Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter StudyAdvances in Therapy, 2018
- Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant RecipientsAmerican Journal of Kidney Diseases, 2018
- Influence of tacrolimus metabolism rate on BKV infection after kidney transplantationScientific Reports, 2016
- Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant RecipientsTransplantation Proceedings, 2016
- Reduced Exposure to Calcineurin Inhibitors in Renal TransplantationNew England Journal of Medicine, 2007
- Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipientsAmerican Journal of Kidney Diseases, 2000
- Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patientsClinical Chemistry, 1996